Recommendations for monitoring during quetiapine treatment
| At baseline |
| Body mass index |
| Waist circumference |
| Blood pressure |
| Fasting glucose |
| Fasting lipids |
| After initiation |
| Electrocardiography |
| Potassium level |
| Extrapyramidal side effects (using the Abnormal Involuntary Movement Scale [AIMS]) |
| At 4, 8, and 12 weeks after initiation |
| Body mass index |
| Three months after initiation |
| Blood pressure |
| Fasting glucose |
| Fasting lipids |
| Routinely at follow-up visits |
| Body mass index |
| Extrapyramidal side effects (using AIMS) |
| Signs of misuse, abuse, or other drug-seeking behavior |
| Annually |
| Blood pressure |
| Fasting glucose |
| Fasting lipids |
| With dose or risk factor changes |
| Electrocardiography |
| Potassium level |
Based on information in reference 20.